Patents by Inventor Xiangping Qian

Xiangping Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER
    Publication number: 20240115585
    Abstract: The present invention relates to methods of treating cancer comprising administering a bufalin derivative compound of Formula I, wherein the compound is administered at least once a week for at least two weeks
    Type: Application
    Filed: November 30, 2023
    Publication date: April 11, 2024
    Inventor: Xiangping QIAN
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20240116880
    Abstract: Chemical entities that are novel compounds, their polymorphs, pharmaceutical compositions, and methods of treatment of cancer are described.
    Type: Application
    Filed: December 1, 2021
    Publication date: April 11, 2024
    Inventor: Xiangping QIAN
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20240092825
    Abstract: Chemical entities that are novel compounds, their polymorphs, pharmaceutical compositions, and methods of treatment of cancer are described.
    Type: Application
    Filed: July 28, 2023
    Publication date: March 21, 2024
    Inventor: Xiangping QIAN
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 11865120
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: January 9, 2024
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20230043970
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: October 20, 2021
    Publication date: February 9, 2023
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS
    Publication number: 20230026651
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 20, 2022
    Publication date: January 26, 2023
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20220354864
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: February 25, 2022
    Publication date: November 10, 2022
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20220339164
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: March 16, 2022
    Publication date: October 27, 2022
    Inventor: Xiangping QIAN
  • Certain chemical entities, compositions, and methods
    Patent number: 11465975
    Abstract: Chemical entities that are kinase inhibitors, their polymorphs, pharmaceutical compositions and methods of treatment of cancer are described herein.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: October 11, 2022
    Assignee: NEUPHARMA, INC
    Inventor: Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20220251049
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: December 10, 2021
    Publication date: August 11, 2022
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • Amino-pyrimidine skeletal muscle modulators
    Patent number: 11369565
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: June 28, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Certain chemical entities, compositions, and methods
    Patent number: 11325940
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: May 10, 2022
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 11304957
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: April 19, 2022
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20220079957
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: August 4, 2021
    Publication date: March 17, 2022
    Inventor: Xiangping QIAN
  • Certain chemical entities, compositions, and methods
    Patent number: 11208388
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: December 28, 2021
    Assignee: NEUPHARMA, INC
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20210163423
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 3, 2021
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20210113593
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Inventor: Xiangping QIAN
  • Certain chemical entities, compositions, and methods
    Patent number: 10947201
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: March 16, 2021
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS
    Publication number: 20210045997
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: February 18, 2021
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20210040048
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: July 21, 2020
    Publication date: February 11, 2021
    Inventors: Xiangping QIAN, Yong-Liang ZHU